Tesla Invests Most On R&D Among Rivals, Least On Advertising https://t.co/HL7pYzsjDu via @insideevs.com
— InsideEVs (@InsideEVs) October 14, 2021
aTyr Pharma Gets FDA Fast Track Status For Systemic Sclerosis Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis (SSc)-associated, interstitial lung disease (ILD).
